This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop

ACT Capital Management established a new position in TG Therapeutics (NASDAQ:TGTX), acquiring 268,875 shares worth $8.015M (representing 6.5% of the fund's $123.67M reportable U.S. equity assets) and making it the fund's fifth-largest holding. TG Therapeutics reported 2025 product sales of BRIUMVI of roughly $606.9M and total revenue of $616.3M, with Q4 U.S. BRIUMVI revenue of $182.7M; the company is guiding ~ $875–900M in global revenue for 2026. Shares trade at $28.58, down ~30% over the past year, and the filing reads as a speculative, contrarian bet that upside to guidance and continued BRIUMVI adoption could drive a turnaround.

Analysis

ACT’s establishment of a material new slot in a small-cap commercial biopharma reads as an event-driven conviction rather than a passive momentum bet — the trade structure implies they expect near-term operational proof points (sales cadence, inventory cadence or a modest guidance raise) to re-rate the equity faster than broader biotech peers. That creates asymmetric payoff: an execution beat or faster-than-expected international rollout can compress perceived clinical/regulatory risk and unlock multiple expansion, while a single-quarter setback would likely be met with outsized downside given the stock’s illiquidity profile.

On competitive dynamics, the core second-order lever is prescriber inertia and payer economics. Rapid frontline adoption by neurologists can be front-loaded into 2–4 quarters, but durable margin improvement requires reducing patient-start friction (auths, hubs) and scaling manufacturing to avoid churn; incumbents with entrenched hospital/infusion relationships are the immediate losers if switching accelerates, but they also have lobby power to slow reimbursement — a negotiation-arbitrage angle worth watching.

Key catalysts and risks live on a clear timeline: quarterly sales cadence and international launch updates (0–12 months) are binary catalysts; payer coverage and label/safety chatter (3–18 months) are binary risks that would reprice the name faster than fundamentals. The path to upside is operational and commercial (volume + margin) rather than new clinical data, which compresses the time horizon for a catalyst-driven payoff but raises sensitivity to execution slippage.

Key Decisions for Investors

• Long TGTX equity (small starter position 1–2% portfolio) with a tight stop at -30% and a 12–18 month price target implying ~2x upside if execution accelerates; rationale: capture asymmetric re-rating if sales/margins beat and international rollouts accelerate.
• Options: buy 12–15 month call calendar (long-dated calls) to cap capital at known downside while preserving upside (target 2:1 asymmetric payoff). Use strike ~25–35 depending on premium; exit on 50–70% premium gain or on confirmed guidance beat.
• Hedge trade: pair long TGTX with short a biotech large-cap ETF (e.g., IBB) size 1:0.5 for 6–12 months to neutralize market/systematic beta and isolate company-specific adoption risk.
• Event hedge for next quarterly print (0–3 months): buy 3–6 month puts or put spreads limiting drawdown to ~20–25% of position size if guidance misses; cost of protection is the price of preserving asymmetric upside in the long-dated calls.
• Contrarian short trigger: if the company issues materially weaker gross-margin guidance or public payer restrictions in major European markets (trigger within 3–6 months), short into that headline with options to exploit forced liquidation and multiple contraction.